Exact Mass: 540.226

Sambacin

C26H36O12 (540.2207)

Sambacin is found in herbs and spices. Sambacin is isolated from Jasminum sambac (Arabian jasmine).

Atorvastatin lactone

C33H33FN2O4 (540.2424)

Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl],cyclic (3®5)-disulfide

C24H36N4O6S2 (540.2076)

Methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-2-naphthalenecarboxylate

C30H36O9 (540.2359)

PA(2:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C27H41O9P (540.2488)

PA(2:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C27H41O9P (540.2488)

PA(2:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/2:0)

C27H41O9P (540.2488)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/2:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C27H41O9P (540.2488)

PA(2:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/2:0)

C27H41O9P (540.2488)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/2:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C27H41O9P (540.2488)

PA(2:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/2:0)

C27H41O9P (540.2488)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/2:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C27H41O9P (540.2488)

PA(2:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/2:0)

C27H41O9P (540.2488)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/2:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Pulcherrin C

C30H36O9 (540.2359)

Pyridomycin

C27H32N4O8 (540.222)

Zumketol

C30H36O9 (540.2359)

Menthiafolin

C26H36O12 (540.2207)

Briaexcavatin S

C26H36O12 (540.2207)

Sesquipinsapol B

C30H36O9 (540.2359)

Foliamenthin

C26H36O12 (540.2207)

Citrumarin C

C33H32O7 (540.2148)

Isovouacapenol E

C34H36O6 (540.2512)

Citrumarin B

C33H32O7 (540.2148)

Tinosposinenside C

C26H36O12 (540.2207)

Norstaminone A

C30H36O9 (540.2359)

Leucadenone A

C33H32O7 (540.2148)

Leucadenone C

C33H32O7 (540.2148)

SCHEMBL1111341

C30H36O9 (540.2359)

MCULE-8476103740

C26H36O12 (540.2207)

6alpha-Acetoxygedunin

C30H36O9 (540.2359)

2alpha-senecioyloxy-3alpha-angeloyloxy-3,4-betaH-bacchotricuneatin

C30H36O9 (540.2359)

Icariside E2

C26H36O12 (540.2207)

(1S,2R)-1-[4-beta-D-glucopyranosyloxy-3-methoxyphenyl]-2-[4-(3-hydroxypropyl)-2-methoxyphenoxy]-1,3-propanediol|(7S,8R)-7,9,9-trihydroxy-3,3-dimethoxy-8-O-4-neolignan-4-O-beta-D-glucopyranoside|(7S,8R)-erythro-7,9,9-tirhydroxy-3,3-dimethoxy-8-O-4-neolignan-4-O-beta-D-glucopyranoside

C26H36O12 (540.2207)

11beta-Acetoxygedunin

C30H36O9 (540.2359)

dichrocepholide D

C30H36O9 (540.2359)

dumsenin

C30H36O9 (540.2359)

Romidepsin

C24H36N4O6S2 (540.2076)

A cyclodepsipeptide consisting of the cyclic disulfide of (2Z)-2-aminobut-2-enoyl, L-valyl, (3S,4E)-3-hydroxy-7-sulfanylhept-4-enoyl, D-valyl and D-cysteinyl residues coupled in sequence and cyclised head-to tail. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XH - Histone deacetylase (hdac) inhibitors C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent D000970 - Antineoplastic Agents

Tamariscinoside B

C26H36O12 (540.2207)

Laboutein

C26H36O12 (540.2207)

2-O-acetylstrictosamide

C28H32N2O9 (540.2108)

andirolide A

C30H36O9 (540.2359)

(1S,5R,6R,9R)-5,12-epoxy-megastigman-3-on-9-ol 9-O-[6-O-galloyl]-beta-D-glucopyranoside|(9R)-megastigman-3-on-5,11-epoxy-9-ol 9-O-(6-O-galloyl)-beta-D-glucopyranoside|macarangioside C

C26H36O12 (540.2207)

(6S,9R)-megastigman-4-en-3-one-6,9-diol 9-O-(6-O-galloyl)-beta-D-glucopyranoside|macarangioside A

C26H36O12 (540.2207)

briaexcavatin L

C26H36O12 (540.2207)

peniciketal A

C30H36O9 (540.2359)

aurisin A

C30H36O9 (540.2359)

7-hydroxy-9-beta-glucopyranosyloxylsecoisolariciresinol|cinnacassoside A

C26H36O12 (540.2207)

7-hydroxy-9-beta-glucopyranosyloxy secoisolariciresinol

C26H36O12 (540.2207)

Heteropsine

C35H28N2O4 (540.2049)

7Z-punaglandin-4-acetate

C27H37ClO9 (540.2126)

11beta,12alpha-diacetoxy-14beta,15beta-epoxyneotecleanin|11??,12??-Diacetoxy-14??,15??-epoxyneotecleanin|zumsin

C30H36O9 (540.2359)

splenocin E

C28H32N2O9 (540.2108)

(20S,22S,23S,24S,25S,26S)-5alpha-chloro-12alpha,22-23,26,24,25-triepoxy-6beta,12beta,17beta,26-tetrahydroxyergosta-1-one|jaborosalactol 26

C28H41ClO8 (540.249)

violide M

C26H36O12 (540.2207)

7S,8S-4,9,9-trihydroxy-3,3-dimethoxy-8-O-4-neolignan-7-O-beta-D-glucopyranoside|8-O-4-neolignan-7-O-beta-glucopyranoside

C26H36O12 (540.2207)

20-Deoxy,3,5-dibenzoyl-Ingenol|20-deoxyingenol-3,5-dibenzoate

C34H36O6 (540.2512)

1-(4-hydroxymethyl-3-methoxyphenyl)-2-<4-(3-beta-D-glucopyranosyloxypropyl)-2-methoxyphenoxy>-1,3-propanediol|1-(4-hydroxymethyl-3-methoxyphenyl)-2-[4-(3-beta-D-glucopyranosyloxypropyl)-2-methoxyphenoxy]-1,3-propanediol

C26H36O12 (540.2207)

2alpha-angeloyloxy-3alpha-senecioyloxy-3,4-betaH-bacchotricuneatin

C30H36O9 (540.2359)

6-O-Acetylstritosamide

C28H32N2O9 (540.2108)

10-acetoxy-1-acevaltrate hydrin

C26H36O12 (540.2207)

Dalcriodain

C33H32O7 (540.2148)

shinjuglycoside B

C26H36O12 (540.2207)

isonimolicinolide

C30H36O9 (540.2359)

Picrasidine R

C30H28N4O6 (540.2009)

splenocin B

C28H32N2O9 (540.2108)

Glu Thr Tyr Glu

C23H32N4O11 (540.2067)

Nimbin_(chemical)

C30H36O9 (540.2359)

Nimbin is a limonoid found in Azadirachta indica. It has a role as a plant metabolite and a pesticide. It is an acetate ester, a limonoid, a member of furans, a cyclic terpene ketone, an enone, a tetracyclic triterpenoid and a methyl ester. Nimbin is a natural product found in Azadirachta indica with data available. A limonoid found in Azadirachta indica.

2-[3-[4-[1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy-3-methoxyphenyl]propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

C30H36O9_2H-Cyclopenta[b]naphtho[2,3-d]furan-10-acetic acid, 5-(acetyloxy)-2-(3-furanyl)-3,3a,4a,5,5a,6,9,9a,10,10a-decahydro-6-(methoxycarbonyl)-1,6,9a,10a-tetramethyl-9-oxo-, methyl ester, (2R,3aR,4aS,5R,6R,9aR,10S,10aR)

C30H36O9 (540.2359)

methyl (1S,2R,4R,8R,9S,10R,13R,15R)-2-(acetyloxy)-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-7-oxo-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadeca-5,11-diene-4-carboxylate

C30H36O9 (540.2359)

2-[3-[4-[1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy-3-methoxyphenyl]propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol [IIN-based: Match]

C26H36O12 (540.2207)

2-[3-[4-[1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy-3-methoxyphenyl]propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol [IIN-based on: CCMSLIB00000849029]

C26H36O12 (540.2207)

methyl (1S,2R,4R,8R,9S,10R,13R,15R)-2-(acetyloxy)-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-7-oxo-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadeca-5,11-diene-4-carboxylate_major

C30H36O9 (540.2359)

methyl (1S,2R,4R,8R,9S,10R,13R,15R)-2-(acetyloxy)-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-7-oxo-16-oxatetracyclo[8.6.0.0³,?.0¹¹,¹?]hexadeca-5,11-diene-4-carboxylate

C30H36O9 (540.2359)

Ala His Gln Trp

C25H32N8O6 (540.2445)

Ala His Trp Gln

C25H32N8O6 (540.2445)

Ala Gln His Trp

C25H32N8O6 (540.2445)

Ala Gln Trp His

C25H32N8O6 (540.2445)

Ala Trp His Gln

C25H32N8O6 (540.2445)

Ala Trp Gln His

C25H32N8O6 (540.2445)

Cys Lys Gln Tyr

C23H36N6O7S (540.2366)

Cys Lys Tyr Gln

C23H36N6O7S (540.2366)

Cys Gln Lys Tyr

C23H36N6O7S (540.2366)

Cys Gln Tyr Lys

C23H36N6O7S (540.2366)

Cys Tyr Lys Gln

C23H36N6O7S (540.2366)

Cys Tyr Gln Lys

C23H36N6O7S (540.2366)

Asp Phe Pro Tyr

C27H32N4O8 (540.222)

Asp Phe Tyr Pro

C27H32N4O8 (540.222)

Asp His Asn Arg

C20H32N10O8 (540.2404)

Asp His Arg Asn

C20H32N10O8 (540.2404)

Asp Ile Met Tyr

C24H36N4O8S (540.2254)

Asp Ile Tyr Met

C24H36N4O8S (540.2254)

Asp Leu Met Tyr

C24H36N4O8S (540.2254)

Asp Leu Tyr Met

C24H36N4O8S (540.2254)

Asp Met Ile Tyr

C24H36N4O8S (540.2254)

Asp Met Leu Tyr

C24H36N4O8S (540.2254)

Asp Met Tyr Ile

C24H36N4O8S (540.2254)

Asp Met Tyr Leu

C24H36N4O8S (540.2254)

Asp Asn His Arg

C20H32N10O8 (540.2404)

Asp Asn Arg His

C20H32N10O8 (540.2404)

Asp Pro Phe Tyr

C27H32N4O8 (540.222)

Asp Pro Tyr Phe

C27H32N4O8 (540.222)

Asp Arg His Asn

C20H32N10O8 (540.2404)

Asp Arg Asn His

C20H32N10O8 (540.2404)

Asp Tyr Phe Pro

C27H32N4O8 (540.222)

Asp Tyr Ile Met

C24H36N4O8S (540.2254)

Asp Tyr Leu Met

C24H36N4O8S (540.2254)

Asp Tyr Met Ile

C24H36N4O8S (540.2254)

Asp Tyr Met Leu

C24H36N4O8S (540.2254)

Asp Tyr Pro Phe

C27H32N4O8 (540.222)

Glu Glu Thr Tyr

C23H32N4O11 (540.2067)

Glu Glu Tyr Thr

C23H32N4O11 (540.2067)

Glu His Gln Gln

C21H32N8O9 (540.2292)

Glu Met Val Tyr

C24H36N4O8S (540.2254)

Glu Met Tyr Val

C24H36N4O8S (540.2254)

Glu Gln His Gln

C21H32N8O9 (540.2292)

Glu Gln Gln His

C21H32N8O9 (540.2292)

Glu Thr Glu Tyr

C23H32N4O11 (540.2067)

Glu Val Met Tyr

C24H36N4O8S (540.2254)

Glu Val Tyr Met

C24H36N4O8S (540.2254)

Glu Tyr Glu Thr

C23H32N4O11 (540.2067)

Glu Tyr Met Val

C24H36N4O8S (540.2254)

Glu Tyr Thr Glu

C23H32N4O11 (540.2067)

Glu Tyr Val Met

C24H36N4O8S (540.2254)

Phe Asp Pro Tyr

C27H32N4O8 (540.222)

Phe Asp Tyr Pro

C27H32N4O8 (540.222)

Phe Phe Met Pro

C28H36N4O5S (540.2406)

Phe Phe Asn Asn

C26H32N6O7 (540.2332)

Phe Phe Pro Met

C28H36N4O5S (540.2406)

Phe His His Thr

C25H32N8O6 (540.2445)

Phe His Thr His

C25H32N8O6 (540.2445)

Phe Ile Met Met

C25H40N4O5S2 (540.244)

Phe Leu Met Met

C25H40N4O5S2 (540.244)

Phe Met Phe Pro

C28H36N4O5S (540.2406)

Phe Met Ile Met

C25H40N4O5S2 (540.244)

Phe Met Leu Met

C25H40N4O5S2 (540.244)

Phe Met Met Ile

C25H40N4O5S2 (540.244)

Phe Met Met Leu

C25H40N4O5S2 (540.244)

Phe Met Pro Phe

C28H36N4O5S (540.2406)

Phe Asn Phe Asn

C26H32N6O7 (540.2332)

Phe Asn Asn Phe

C26H32N6O7 (540.2332)

Phe Pro Asp Tyr

C27H32N4O8 (540.222)

Phe Pro Phe Met

C28H36N4O5S (540.2406)

Phe Pro Met Phe

C28H36N4O5S (540.2406)

Phe Pro Tyr Asp

C27H32N4O8 (540.222)

Phe Thr His His

C25H32N8O6 (540.2445)

Phe Tyr Asp Pro

C27H32N4O8 (540.222)

Phe Tyr Pro Asp

C27H32N4O8 (540.222)

His Ala Gln Trp

C25H32N8O6 (540.2445)

His Ala Trp Gln

C25H32N8O6 (540.2445)

His Asp Asn Arg

C20H32N10O8 (540.2404)

His Asp Arg Asn

C20H32N10O8 (540.2404)

His Glu Gln Gln

C21H32N8O9 (540.2292)

His Phe His Thr

C25H32N8O6 (540.2445)

His Phe Thr His

C25H32N8O6 (540.2445)

His His Phe Thr

C25H32N8O6 (540.2445)

His His Thr Phe

C25H32N8O6 (540.2445)

His Asn Asp Arg

C20H32N10O8 (540.2404)

His Asn Arg Asp

C20H32N10O8 (540.2404)

His Gln Ala Trp

C25H32N8O6 (540.2445)

His Gln Glu Gln

C21H32N8O9 (540.2292)

His Gln Gln Glu

C21H32N8O9 (540.2292)

His Gln Trp Ala

C25H32N8O6 (540.2445)

His Arg Asp Asn

C20H32N10O8 (540.2404)

His Arg Asn Asp

C20H32N10O8 (540.2404)

His Thr Phe His

C25H32N8O6 (540.2445)

His Thr His Phe

C25H32N8O6 (540.2445)

His Trp Ala Gln

C25H32N8O6 (540.2445)

His Trp Gln Ala

C25H32N8O6 (540.2445)

Ile Asp Met Tyr

C24H36N4O8S (540.2254)

Ile Asp Tyr Met

C24H36N4O8S (540.2254)

Ile Phe Met Met

C25H40N4O5S2 (540.244)

Ile Met Asp Tyr

C24H36N4O8S (540.2254)

Ile Met Phe Met

C25H40N4O5S2 (540.244)

Ile Met Met Phe

C25H40N4O5S2 (540.244)

Ile Met Tyr Asp

C24H36N4O8S (540.2254)

Ile Tyr Asp Met

C24H36N4O8S (540.2254)

Ile Tyr Met Asp

C24H36N4O8S (540.2254)

Lys Cys Gln Tyr

C23H36N6O7S (540.2366)

Lys Cys Tyr Gln

C23H36N6O7S (540.2366)

Lys Gln Cys Tyr

C23H36N6O7S (540.2366)

Lys Gln Tyr Cys

C23H36N6O7S (540.2366)

Lys Tyr Cys Gln

C23H36N6O7S (540.2366)

Lys Tyr Gln Cys

C23H36N6O7S (540.2366)

Leu Asp Met Tyr

C24H36N4O8S (540.2254)

Leu Asp Tyr Met

C24H36N4O8S (540.2254)

Leu Phe Met Met

C25H40N4O5S2 (540.244)

Leu Met Asp Tyr

C24H36N4O8S (540.2254)

Leu Met Phe Met

C25H40N4O5S2 (540.244)

Leu Met Met Phe

C25H40N4O5S2 (540.244)

Leu Met Tyr Asp

C24H36N4O8S (540.2254)

Leu Tyr Asp Met

C24H36N4O8S (540.2254)

Leu Tyr Met Asp

C24H36N4O8S (540.2254)

Met Asp Ile Tyr

C24H36N4O8S (540.2254)

Met Asp Leu Tyr

C24H36N4O8S (540.2254)

Met Asp Tyr Ile

C24H36N4O8S (540.2254)

Met Asp Tyr Leu

C24H36N4O8S (540.2254)

Met Glu Val Tyr

C24H36N4O8S (540.2254)

Met Glu Tyr Val

C24H36N4O8S (540.2254)

Met Phe Phe Pro

C28H36N4O5S (540.2406)

Met Phe Ile Met

C25H40N4O5S2 (540.244)

Met Phe Leu Met

C25H40N4O5S2 (540.244)

Met Phe Met Ile

C25H40N4O5S2 (540.244)

Met Phe Met Leu

C25H40N4O5S2 (540.244)

Met Phe Pro Phe

C28H36N4O5S (540.2406)

Met Ile Asp Tyr

C24H36N4O8S (540.2254)

Met Ile Phe Met

C25H40N4O5S2 (540.244)

Met Ile Met Phe

C25H40N4O5S2 (540.244)

Met Ile Tyr Asp

C24H36N4O8S (540.2254)

Met Leu Asp Tyr

C24H36N4O8S (540.2254)

Met Leu Phe Met

C25H40N4O5S2 (540.244)

Met Leu Met Phe

C25H40N4O5S2 (540.244)

Met Leu Tyr Asp

C24H36N4O8S (540.2254)

Met Met Phe Ile

C25H40N4O5S2 (540.244)

Met Met Phe Leu

C25H40N4O5S2 (540.244)

Met Met Ile Phe

C25H40N4O5S2 (540.244)

Met Met Leu Phe

C25H40N4O5S2 (540.244)

Met Met Pro Tyr

C24H36N4O6S2 (540.2076)

Met Met Tyr Pro

C24H36N4O6S2 (540.2076)

Met Pro Phe Phe

C28H36N4O5S (540.2406)

Met Pro Met Tyr

C24H36N4O6S2 (540.2076)

Met Pro Tyr Met

C24H36N4O6S2 (540.2076)

Met Val Glu Tyr

C24H36N4O8S (540.2254)

Met Val Tyr Glu

C24H36N4O8S (540.2254)

Met Tyr Asp Ile

C24H36N4O8S (540.2254)

Met Tyr Asp Leu

C24H36N4O8S (540.2254)

Met Tyr Glu Val

C24H36N4O8S (540.2254)

Met Tyr Ile Asp

C24H36N4O8S (540.2254)

Met Tyr Leu Asp

C24H36N4O8S (540.2254)

Met Tyr Met Pro

C24H36N4O6S2 (540.2076)

Met Tyr Pro Met

C24H36N4O6S2 (540.2076)

Met Tyr Val Glu

C24H36N4O8S (540.2254)

Asn Asp His Arg

C20H32N10O8 (540.2404)

Asn Asp Arg His

C20H32N10O8 (540.2404)

Asn Phe Phe Asn

C26H32N6O7 (540.2332)

Asn Phe Asn Phe

C26H32N6O7 (540.2332)

Asn His Asp Arg

C20H32N10O8 (540.2404)

Asn His Arg Asp

C20H32N10O8 (540.2404)

Asn Asn Phe Phe

C26H32N6O7 (540.2332)

Asn Arg Asp His

C20H32N10O8 (540.2404)

Asn Arg His Asp

C20H32N10O8 (540.2404)

Pro Asp Phe Tyr

C27H32N4O8 (540.222)

Pro Asp Tyr Phe

C27H32N4O8 (540.222)

Pro Phe Asp Tyr

C27H32N4O8 (540.222)

Pro Phe Phe Met

C28H36N4O5S (540.2406)

Pro Phe Met Phe

C28H36N4O5S (540.2406)

Pro Phe Tyr Asp

C27H32N4O8 (540.222)

Pro Met Phe Phe

C28H36N4O5S (540.2406)

Pro Met Met Tyr

C24H36N4O6S2 (540.2076)

Pro Met Tyr Met

C24H36N4O6S2 (540.2076)

Pro Tyr Asp Phe

C27H32N4O8 (540.222)

Pro Tyr Phe Asp

C27H32N4O8 (540.222)

Pro Tyr Met Met

C24H36N4O6S2 (540.2076)

Gln Ala His Trp

C25H32N8O6 (540.2445)

Gln Ala Trp His

C25H32N8O6 (540.2445)

Gln Cys Lys Tyr

C23H36N6O7S (540.2366)

Gln Cys Tyr Lys

C23H36N6O7S (540.2366)

Gln Glu His Gln

C21H32N8O9 (540.2292)

Gln Glu Gln His

C21H32N8O9 (540.2292)

Gln His Ala Trp

C25H32N8O6 (540.2445)

Gln His Glu Gln

C21H32N8O9 (540.2292)

Gln His Gln Glu

C21H32N8O9 (540.2292)

Gln His Trp Ala

C25H32N8O6 (540.2445)

Gln Lys Cys Tyr

C23H36N6O7S (540.2366)

Gln Lys Tyr Cys

C23H36N6O7S (540.2366)

Gln Gln Glu His

C21H32N8O9 (540.2292)

Gln Gln His Glu

C21H32N8O9 (540.2292)

Gln Trp Ala His

C25H32N8O6 (540.2445)

Gln Trp His Ala

C25H32N8O6 (540.2445)

Gln Tyr Cys Lys

C23H36N6O7S (540.2366)

Gln Tyr Lys Cys

C23H36N6O7S (540.2366)

Arg Asp His Asn

C20H32N10O8 (540.2404)

Arg Asp Asn His

C20H32N10O8 (540.2404)

Arg His Asp Asn

C20H32N10O8 (540.2404)

Arg His Asn Asp

C20H32N10O8 (540.2404)

Arg Asn Asp His

C20H32N10O8 (540.2404)

Arg Asn His Asp

C20H32N10O8 (540.2404)

Thr Glu Glu Tyr

C23H32N4O11 (540.2067)

Thr Glu Tyr Glu

C23H32N4O11 (540.2067)

Thr Phe His His

C25H32N8O6 (540.2445)

Thr His Phe His

C25H32N8O6 (540.2445)

Thr His His Phe

C25H32N8O6 (540.2445)

Thr Tyr Glu Glu

C23H32N4O11 (540.2067)

Val Glu Met Tyr

C24H36N4O8S (540.2254)

Val Glu Tyr Met

C24H36N4O8S (540.2254)

Val Met Glu Tyr

C24H36N4O8S (540.2254)

Val Met Tyr Glu

C24H36N4O8S (540.2254)

Val Tyr Glu Met

C24H36N4O8S (540.2254)

Val Tyr Met Glu

C24H36N4O8S (540.2254)

Trp Ala His Gln

C25H32N8O6 (540.2445)

Trp Ala Gln His

C25H32N8O6 (540.2445)

Trp His Ala Gln

C25H32N8O6 (540.2445)

Trp His Gln Ala

C25H32N8O6 (540.2445)

Trp Gln Ala His

C25H32N8O6 (540.2445)

Trp Gln His Ala

C25H32N8O6 (540.2445)

Tyr Cys Lys Gln

C23H36N6O7S (540.2366)

Tyr Cys Gln Lys

C23H36N6O7S (540.2366)

Tyr Asp Phe Pro

C27H32N4O8 (540.222)

Tyr Asp Ile Met

C24H36N4O8S (540.2254)

Tyr Asp Leu Met

C24H36N4O8S (540.2254)

Tyr Asp Met Ile

C24H36N4O8S (540.2254)

Tyr Asp Met Leu

C24H36N4O8S (540.2254)

Tyr Asp Pro Phe

C27H32N4O8 (540.222)

Tyr Glu Glu Thr

C23H32N4O11 (540.2067)

Tyr Glu Met Val

C24H36N4O8S (540.2254)

Tyr Glu Thr Glu

C23H32N4O11 (540.2067)

Tyr Glu Val Met

C24H36N4O8S (540.2254)

Tyr Phe Asp Pro

C27H32N4O8 (540.222)

Tyr Phe Pro Asp

C27H32N4O8 (540.222)

Tyr Ile Asp Met

C24H36N4O8S (540.2254)

Tyr Ile Met Asp

C24H36N4O8S (540.2254)

Tyr Lys Cys Gln

C23H36N6O7S (540.2366)

Tyr Lys Gln Cys

C23H36N6O7S (540.2366)

Tyr Leu Asp Met

C24H36N4O8S (540.2254)

Tyr Leu Met Asp

C24H36N4O8S (540.2254)

Tyr Met Asp Ile

C24H36N4O8S (540.2254)

Tyr Met Asp Leu

C24H36N4O8S (540.2254)

Tyr Met Glu Val

C24H36N4O8S (540.2254)

Tyr Met Ile Asp

C24H36N4O8S (540.2254)

Tyr Met Leu Asp

C24H36N4O8S (540.2254)

Tyr Met Met Pro

C24H36N4O6S2 (540.2076)

Tyr Met Pro Met

C24H36N4O6S2 (540.2076)

Tyr Met Val Glu

C24H36N4O8S (540.2254)

Tyr Pro Asp Phe

C27H32N4O8 (540.222)

Tyr Pro Phe Asp

C27H32N4O8 (540.222)

Tyr Pro Met Met

C24H36N4O6S2 (540.2076)

Tyr Gln Cys Lys

C23H36N6O7S (540.2366)

Tyr Gln Lys Cys

C23H36N6O7S (540.2366)

Tyr Thr Glu Glu

C23H32N4O11 (540.2067)

Tyr Val Glu Met

C24H36N4O8S (540.2254)

Tyr Val Met Glu

C24H36N4O8S (540.2254)

Galβ1-3GalNAcα-Thr

C21H36N2O14 (540.2166)

12R-acetoxy-punaglandin 4

C27H37ClO9 (540.2126)

12R-acetoxy-7Z-punaglandin 4

C27H37ClO9 (540.2126)

12S-acetoxy-punaglandin 5

C27H37ClO9 (540.2126)

Leucadenone B

C33H32O7 (540.2148)

Leucadenone D

C33H32O7 (540.2148)

Sambacin

C26H36O12 (540.2207)

12R-acetoxy-punaglandin 4

C27H37O9Cl (540.2126)

12R-acetoxy-7Z-punaglandin 4

C27H37O9Cl (540.2126)

12S-acetoxy-punaglandin 5

C27H37O9Cl (540.2126)

4,4-(1,4-phenylene)bis(2,2:6,2-terpyridine)

C36H24N6 (540.2062)

Olmesartan medoxomil impurity C

C29H28N6O5 (540.2121)

Atorvastatin lactone

C33H33FN2O4 (540.2424)

Atorvastatin lactone is a proagent form of atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor[1].

Acofide trihydrate

C21H37ClN4O8S (540.2021)

D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D005765 - Gastrointestinal Agents D004791 - Enzyme Inhibitors

3,4,5,6-TETRAKIS(BENZYLOXY)-1,2-CYCLOHEXANEDIOL

C34H36O6 (540.2512)

2,3,4,6-tetra-o-benzyl-d-galactopyranose

C34H36O6 (540.2512)

2,3,4,6-tetra-o-benzyl-alpha-d-mannopyranose

C34H36O6 (540.2512)

4-[4-[4-amino-2-(trifluoromethyl)phenoxy]-2,5-ditert-butylphenoxy]-3-(trifluoromethyl)aniline

C28H30F6N2O2 (540.2211)

1,3-DI([2,2:6,2-TERPYRIDIN]-4-YL)BENZENE

C36H24N6 (540.2062)

2,3,4,6-Tetra-O-benzyl-D-glucopyranose

C34H36O6 (540.2512)

1,2,3,4-TETRABENZYL-BETA-D-GLUCOPYRANOSE

C34H36O6 (540.2512)

FMOC-METRP(BOC)-OH

C32H32N2O6 (540.226)

(2S,3S)-3-AMINO-2-HYDROXYHEPTANOICACID

C34H36O4S (540.2334)

Fmoc-α-Me-Trp(Boc)-OH

C32H32N2O6 (540.226)

N-[(1S)-1-[[[(4R,7S)-Hexahydro-7-methyl-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-2-benzofurancarboxamide

C27H32N4O6S (540.2042)

Relacatib

C27H32N4O6S (540.2042)

C471 - Enzyme Inhibitor > C783 - Protease Inhibitor COVID info from Guide to PHARMACOLOGY Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

Methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-2-naphthalenecarboxylate

C30H36O9 (540.2359)

2-[3-[4-[1,3-Dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy-3-methoxyphenyl]propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

PA(2:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C27H41O9P (540.2488)

PA(2:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C27H41O9P (540.2488)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/2:0)

C27H41O9P (540.2488)

PA(2:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C27H41O9P (540.2488)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/2:0)

C27H41O9P (540.2488)

PA(2:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C27H41O9P (540.2488)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/2:0)

C27H41O9P (540.2488)

PA(2:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C27H41O9P (540.2488)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/2:0)

C27H41O9P (540.2488)

Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl],cyclic (3 not not(R)ao radicalu5)-disulfide

C24H36N4O6S2 (540.2076)

5-(2-hydroxy-5-methylbenzoyl)-N,1-bis[2-(4-methoxyphenyl)ethyl]-2-oxopyridine-3-carboxamide

C32H32N2O6 (540.226)

(4S,5S)-5-[2-(azidomethyl)phenyl]-4-[[2-(azidomethyl)phenyl]methyl]-2-[4-(3-hydroxypropoxy)phenyl]-5H-oxazole-4-carboxamide

C28H28N8O4 (540.2233)

3-fluoro-N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

3-fluoro-N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

3-fluoro-N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

3-fluoro-N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

2-fluoro-N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

2-fluoro-N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

2-fluoro-N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

2-fluoro-N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

2-fluoro-N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

4-fluoro-N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

4-fluoro-N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

3-fluoro-N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

4-fluoro-N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

4-fluoro-N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

2-fluoro-N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

(1R)-1-(benzenesulfonyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide

C28H36N4O5S (540.2406)

3-fluoro-N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

3-fluoro-N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

4-fluoro-N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

4-fluoro-N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

4-fluoro-N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

2-fluoro-N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylbenzenesulfonamide

C29H33FN2O5S (540.2094)

(1S)-1-(benzenesulfonyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide

C28H36N4O5S (540.2406)

(1R,8E,9Z,14S,15S,17R)-8-ethylidene-15-[(2R)-1-hydroxypropan-2-yl]-17-methyl-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,6,12-trioxatricyclo[12.2.1.04,9]heptadeca-4,9-diene-3,11-dione

C26H36O12 (540.2207)

20-carboxy-leukotriene B4-(beta-D-glucuronide)(2-)

C26H36O12-2 (540.2207)

20-hydroxy-20-oxoleukotriene B4-20-(beta-D-glucuronide)(2-)

C26H36O12 (540.2207)

A leukotriene anion obtained by deprotonation of the carboxylic acid functions of 20-hydroxy-20-oxoleukotriene B4-20-(beta-D-glucuronide); major species at pH 7.3.

PA 18:4/6:2;O

C27H41O9P (540.2488)

PA 20:5/4:1;O

C27H41O9P (540.2488)

PA 24:6;O

C27H41O9P (540.2488)

PEth 22:6;O

C27H41O9P (540.2488)

PM 23:6;O

C27H41O9P (540.2488)

ST 20:3;O6;GlcA

C26H36O12 (540.2207)

ST 20:4;O7;Hex

C26H36O12 (540.2207)

ST 26:5;O7;S

C26H36O10S (540.2029)

ST 27:4;O6;S

C27H40O9S (540.2393)

Velusetrag (hydrochloride)

C25H37ClN4O5S (540.2173)

Velusetrag (TD-5108) hydrochloride is an orally active, potent and selective agonist of serotonin 5-HT4 receptor (5-HT4R), with a pKi of 7.7. Velusetrag hydrochloride exhibits no affinity (Ki>10 μM) for 5-HT2A and 5-HT2B receptors. Velusetrag hydrochloride can be used for the research of gastrointestinal diseases and Parkinson's disease[1][2][3][4][5].

(1s,4r,5r,7s,11r,13s,16s,17s,18s,19r)-4,5,17-trihydroxy-14,18-dimethyl-6-methylidene-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,10-dioxapentacyclo[9.8.0.0¹,⁷.0⁴,¹⁹.0¹³,¹⁸]nonadec-14-en-9-one

C26H36O12 (540.2207)

(1r,4br,5s,6r,6ar,10ar,10br,12ar)-5-(acetyloxy)-1-(furan-3-yl)-1-hydroxy-4b,7,7,10a,12a-pentamethyl-3,8-dioxo-5h,6h,6ah,10bh,11h,12h-naphtho[2,1-f]isochromen-6-yl acetate

C30H36O9 (540.2359)

methyl (3s,4as,5r,6r,6ar,7s,11as,11br)-6-(acetyloxy)-3-(benzoyloxy)-4a,5-dihydroxy-4,4,11b-trimethyl-1h,2h,3h,5h,6h,6ah,7h,11h,11ah-phenanthro[3,2-b]furan-7-carboxylate

C30H36O9 (540.2359)

15-[(1z)-2-(7-hydroxy-2-oxochromen-6-yl)ethenyl]-11,11,15-trimethyl-8-(2-methylbut-3-en-2-yl)-6,10,16-trioxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1,3,7,9(17)-tetraen-5-one

C33H32O7 (540.2148)

n-[(2r,3s,6s,7r,8r)-7-(benzoyloxy)-8-butyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-3-yl]-2-hydroxy-3-[(hydroxymethylidene)amino]benzenecarboximidic acid

C28H32N2O9 (540.2108)

[(2r,3s,4s,5r,6s)-6-{[(1s,18s,19r,20s)-19-ethenyl-14-oxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-18-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

C28H32N2O9 (540.2108)

2-({19-ethenyl-14-oxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-18-yl}oxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl acetate

C28H32N2O9 (540.2108)

(13s,15r)-15-[(1e)-2-(7-hydroxy-2-oxochromen-8-yl)ethenyl]-11,11,15-trimethyl-8-(2-methylbut-3-en-2-yl)-6,10,16-trioxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1,3,7,9(17)-tetraen-5-one

C33H32O7 (540.2148)

4,5,17-trihydroxy-14,18-dimethyl-6-methylidene-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,10-dioxapentacyclo[9.8.0.0¹,⁷.0⁴,¹⁹.0¹³,¹⁸]nonadec-14-en-9-one

C26H36O12 (540.2207)

(2r,3r,4s,5s,6r)-2-[3-(4-{[(1s,2r)-1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy}-3-methoxyphenyl)propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

(13s,15r)-15-[(1e)-2-(7-hydroxy-2-oxochromen-6-yl)ethenyl]-11,11,15-trimethyl-8-(2-methylbut-3-en-2-yl)-6,10,16-trioxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1,3,7,9(17)-tetraen-5-one

C33H32O7 (540.2148)

20-(acetyloxy)-17-(furan-3-yl)-8,8,12,18-tetramethyl-4,11-dioxo-7,14-dioxahexacyclo[10.8.0.0²,⁶.0²,⁹.0¹³,¹⁵.0¹³,¹⁸]icosan-19-yl acetate

C30H36O9 (540.2359)

[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-{[(2r)-4-[(1s)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]butan-2-yl]oxy}oxan-2-yl]methyl 3,4,5-trihydroxybenzoate

C26H36O12 (540.2207)

4,7-bis[(acetyloxy)methyl]-7-hydroxy-6-[(3-methylbutanoyl)oxy]-1h,6h,7ah-cyclopenta[c]pyran-1-yl 3-(acetyloxy)-3-methylbutanoate

C26H36O12 (540.2207)

10-acetoxy-1-acevaltratehydrin

C26H36O12 (540.2207)

{"Ingredient_id": "HBIN000041","Ingredient_name": "10-acetoxy-1-acevaltratehydrin","Alias": "NA","Ingredient_formula": "C26H36O12","Ingredient_Smile": "CC(C)CC(=O)OC1C=C2C(C1(COC(=O)C)O)C(OC=C2COC(=O)C)OC(=O)CC(C)(C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "121","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

6-o-acetylstritosamide

C28H32N2O9 (540.2108)

{"Ingredient_id": "HBIN012613","Ingredient_name": "6-o-acetylstritosamide","Alias": "NA","Ingredient_formula": "C28H32N2O9","Ingredient_Smile": "CC=C1C2CC3C4=C(CCN3C(=O)C2=COC1OC5C(C(C(C(O5)COC(=O)C)O)O)O)C6=CC=CC=C6N4","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "515","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

7,9,9'-trihydroxy-3,3'-dimethoxy-8-o-4'-neo-lignan-4-o-β-d-glucopyranoside

C26H36O12 (540.2207)

{"Ingredient_id": "HBIN013000","Ingredient_name": "7,9,9'-trihydroxy-3,3'-dimethoxy-8-o-4'-neo-lignan-4-o-\u03b2-d-glucopyranoside","Alias": "NA","Ingredient_formula": "C26H36O12","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21698","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

3-(2-{6a-hydroxy-6,9a-dimethyl-2,9-dioxo-4h,5h,6h,9bh-azuleno[4,5-b]furan-3-yl}ethyl)-3,6a-dihydroxy-6,9a-dimethyl-3ah,4h,5h,6h,9bh-azuleno[4,5-b]furan-2,9-dione

C30H36O9 (540.2359)

(13r,15s)-15-[(1e)-2-(7-hydroxy-2-oxochromen-8-yl)ethenyl]-11,11,15-trimethyl-8-(2-methylbut-3-en-2-yl)-6,10,16-trioxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1,3,7,9(17)-tetraen-5-one

C33H32O7 (540.2148)

n-[(2z,5r,6s,9s,10r,11r)-2-(butan-2-ylidene)-7,10-dihydroxy-5,11-dimethyl-3,12-dioxo-9-(pyridin-3-ylmethyl)-1,4-dioxa-8-azacyclododec-7-en-6-yl]-3-hydroxypyridine-2-carboximidic acid

C27H32N4O8 (540.222)

(1s,2r,4s,7s,8s,10s,11r,12s,17r,19r)-19-(acetyloxy)-7-(furan-3-yl)-1,8,12,16,16-pentamethyl-5,15-dioxo-3,6-dioxapentacyclo[9.8.0.0²,⁴.0²,⁸.0¹²,¹⁷]nonadec-13-en-10-yl acetate

C30H36O9 (540.2359)

(1r,2r,6s,9r,12r,13r,15r,17s,18r,19r,20r)-20-(acetyloxy)-17-(furan-3-yl)-8,8,12,18-tetramethyl-4,11-dioxo-7,14-dioxahexacyclo[10.8.0.0²,⁶.0²,⁹.0¹³,¹⁵.0¹³,¹⁸]icosan-19-yl acetate

C30H36O9 (540.2359)

(2r,3r,4s,5s,6r)-2-[3-(4-{[(1r,2s)-1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy}-3-methoxyphenyl)propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

(1s,6s,7r,7as)-4,7-bis[(acetyloxy)methyl]-7-hydroxy-6-[(3-methylbutanoyl)oxy]-1h,6h,7ah-cyclopenta[c]pyran-1-yl 3-(acetyloxy)-3-methylbutanoate

C26H36O12 (540.2207)

2-[3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2-methoxyphenoxy]propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

7,9-bis(acetyloxy)-4,5,11-trihydroxy-4,8,12,17-tetramethyl-16-oxo-15,18-dioxatetracyclo[12.4.0.0¹,¹⁷.0³,⁸]octadec-12-en-2-yl acetate

C26H36O12 (540.2207)

methyl 2-{2-[4,5-bis(acetyloxy)-3-(furan-3-yl)-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxiren-6-yl]-6,6-dimethyl-5-oxocyclohex-3-en-1-yl}acetate

C30H36O9 (540.2359)

(3s,3ar,6s,6as,9as,9br)-3-{2-[(6s,6as,9as,9br)-6a-hydroxy-6,9a-dimethyl-2,9-dioxo-4h,5h,6h,9bh-azuleno[4,5-b]furan-3-yl]ethyl}-3,6a-dihydroxy-6,9a-dimethyl-3ah,4h,5h,6h,9bh-azuleno[4,5-b]furan-2,9-dione

C30H36O9 (540.2359)

15-[(1e)-2-(7-hydroxy-2-oxochromen-8-yl)ethenyl]-11,11,15-trimethyl-8-(2-methylbut-3-en-2-yl)-6,10,16-trioxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1,3,7,9(17)-tetraen-5-one

C33H32O7 (540.2148)

6-(acetyloxy)-1-(furan-3-yl)-1-hydroxy-4b,7,7,10a,12a-pentamethyl-3,8-dioxo-5h,6h,6ah,10bh,11h,12h-naphtho[2,1-f]isochromen-5-yl acetate

C30H36O9 (540.2359)

methyl 6-(acetyloxy)-3-(benzoyloxy)-4a,5-dihydroxy-4,4,11b-trimethyl-1h,2h,3h,5h,6h,6ah,7h,11h,11ah-phenanthro[3,2-b]furan-7-carboxylate

C30H36O9 (540.2359)

(1s,2s,4s,6s,9r,12r,16s,17s,18r,19r)-19-(acetyloxy)-16-(furan-3-yl)-4-hydroxy-8,8,12,17-tetramethyl-3,11-dioxo-7-oxapentacyclo[10.7.0.0²,⁶.0²,⁹.0¹³,¹⁷]nonadec-13-en-18-yl acetate

C30H36O9 (540.2359)

6-hydroxy-9-{6-hydroxy-4-isopropyl-3-oxo-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-9-yl}-4-methyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C30H32N6O4 (540.2485)

(1s,4r,7r,9s)-6-hydroxy-9-[(1r,4s,7s)-6-hydroxy-4-methyl-3-oxo-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-9-yl]-4-isopropyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C30H32N6O4 (540.2485)

2-(4-{1,3-dihydroxy-2-[4-(3-hydroxypropyl)-2-methoxyphenoxy]propyl}-2-methoxyphenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

(1r,6r,7s,7ar)-4,7-bis[(acetyloxy)methyl]-7-hydroxy-6-[(3-methylbutanoyl)oxy]-1h,6h,7ah-cyclopenta[c]pyran-1-yl 3-(acetyloxy)-3-methylbutanoate

C26H36O12 (540.2207)

2-[(1s,2s)-1-{5-[(1r)-1-(2-hydroxyphenyl)prop-2-en-1-yl]-2,4-dimethoxyphenoxy}-1-phenylpropan-2-yl]-5-methoxycyclohexa-2,5-diene-1,4-dione

C33H32O7 (540.2148)

methyl 2-[(1r)-2-[(1as,3s,3ar,4r,5s,6r)-4,5-bis(acetyloxy)-3-(furan-3-yl)-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxiren-6-yl]-6,6-dimethyl-5-oxocyclohex-3-en-1-yl]acetate

C30H36O9 (540.2359)

15-[2-(7-hydroxy-2-oxochromen-8-yl)ethenyl]-11,11,15-trimethyl-8-(2-methylbut-3-en-2-yl)-6,10,16-trioxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1,3,7,9(17)-tetraen-5-one

C33H32O7 (540.2148)

(1s,3bs,4r,5ar,9as,9bs,11ar)-4-(acetyloxy)-1-[(2r)-2-hydroxy-5-oxo-2h-furan-3-yl]-3b,6,6,9a,11a-pentamethyl-2,7-dioxo-4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl acetate

C30H36O9 (540.2359)

n-[(2e)-2-(butan-2-ylidene)-7,10-dihydroxy-5,11-dimethyl-3,12-dioxo-9-(pyridin-3-ylmethyl)-1,4-dioxa-8-azacyclododec-7-en-6-yl]-3-hydroxypyridine-2-carboximidic acid

C27H32N4O8 (540.222)

7-ethylidene-6,9,19,22-tetrahydroxy-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricosa-5,8,16,19,22-pentaen-3-one

C24H36N4O6S2 (540.2076)

(1s,2r,4s,7s,8s,11r,12r,17r,18r,19s)-19-(acetyloxy)-7-(furan-3-yl)-1,8,12,16,16-pentamethyl-5,15-dioxo-3,6-dioxapentacyclo[9.8.0.0²,⁴.0²,⁸.0¹²,¹⁷]nonadec-13-en-18-yl acetate

C30H36O9 (540.2359)

[6-(acetyloxy)-9,12-dihydroxy-5a,8,11a-trimethyl-1-oxo-3-phenyl-6,7,7a,9,10,11,11b,12-octahydro-2,5-dioxatetraphen-8-yl]methyl acetate

C30H36O9 (540.2359)

(1r,2s,3s,4as,6r,8r,8as)-2,6-bis(acetyloxy)-8-[(1e)-2-ethenyl-3-oxobut-1-en-1-yl]-3-hydroxy-4,4,8a-trimethyl-7-oxo-hexahydro-1h-naphthalen-1-yl benzoate

C30H36O9 (540.2359)

{6-[(4-{1,5-dimethyl-3-oxo-6-oxabicyclo[3.2.1]octan-8-yl}butan-2-yl)oxy]-3,4,5-trihydroxyoxan-2-yl}methyl 3,4,5-trihydroxybenzoate

C26H36O12 (540.2207)

8-[(3-ethoxy-6,8-dihydroxy-1-oxo-3-pentyl-4h-2-benzopyran-5-yl)oxy]-6-hydroxy-3-pentylisochromen-1-one

C30H36O9 (540.2359)

[(5as,6s,7ar,8r,9s,11as,11bs,12r)-6-(acetyloxy)-9,12-dihydroxy-5a,8,11a-trimethyl-1-oxo-3-phenyl-6,7,7a,9,10,11,11b,12-octahydro-2,5-dioxatetraphen-8-yl]methyl acetate

C30H36O9 (540.2359)

(2r,3r)-2-{[(2s,3r)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-7-methoxy-2,3-dihydro-1-benzofuran-5-yl]methyl}-3-[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol

C30H36O9 (540.2359)

19-(acetyloxy)-16-(furan-3-yl)-4-hydroxy-8,8,12,17-tetramethyl-3,11-dioxo-7-oxapentacyclo[10.7.0.0²,⁶.0²,⁹.0¹³,¹⁷]nonadec-13-en-18-yl acetate

C30H36O9 (540.2359)

2-[3-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2-methoxyphenoxy]propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

(3,4,5-trihydroxy-6-{[4-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)butan-2-yl]oxy}oxan-2-yl)methyl 3,4,5-trihydroxybenzoate

C26H36O12 (540.2207)

(2s,4ar,6as,7r,9s,10r,10ar,10bs)-2-(furan-3-yl)-9-hydroxy-10b-methyl-4-oxo-7-{[(2r,3r,4s,5s,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-decahydro-1h-naphtho[2,1-c]pyran-10-yl acetate

C26H36O12 (540.2207)

(3r,4as,5r,6s)-5-ethenyl-1-oxo-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3h,4h,4ah,5h,6h-pyrano[3,4-c]pyran-3-yl (2e,6e)-8-hydroxy-2,6-dimethylocta-2,6-dienoate

C26H36O12 (540.2207)

(2s,3r,4s,5s,6r)-2-{[(1s,18s,19r,20s)-19-ethenyl-14-oxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-18-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl acetate

C28H32N2O9 (540.2108)

(1s,2r,3s,4s,7s,8z,11r,12r,13s,16r,17s)-11,12-bis(acetyloxy)-3,4,16,17-tetrahydroxy-4,9,13,17-tetramethyl-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadeca-8,14-dien-2-yl acetate

C26H36O12 (540.2207)

(2r,3r,4s,5s,6r)-2-[(1s,2s)-3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2-methoxyphenoxy]propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

2-[3-(4-{[1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy}-3-methoxyphenyl)propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

6-[(1's,2r,4s,6s,13'r,15's)-4,9'-dihydroxy-6,10',15'-trimethyl-6',12',14'-trioxaspiro[oxane-2,5'-tetracyclo[11.3.1.0²,¹¹.0³,⁸]heptadecane]-2',8',10'-trien-13'-ylmethyl]-2,4-dihydroxy-3-methylbenzaldehyde

C30H36O9 (540.2359)

4-(acetyloxy)-1-(2-hydroxy-5-oxo-2h-furan-3-yl)-3b,6,6,9a,11a-pentamethyl-2,7-dioxo-4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl acetate

C30H36O9 (540.2359)

(3s,4as,5r,6s)-5-ethenyl-1-oxo-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3h,4h,4ah,5h,6h-pyrano[3,4-c]pyran-3-yl (2e,6e)-8-hydroxy-2,6-dimethylocta-2,6-dienoate

C26H36O12 (540.2207)

n-[(3s,4r,7r,8r,9s)-7-benzyl-4,9-dimethyl-8-[(2-methylpropanoyl)oxy]-2,6-dioxo-1,5-dioxonan-3-yl]-2-hydroxy-3-[(hydroxymethylidene)amino]benzenecarboximidic acid

C28H32N2O9 (540.2108)

6-{4,9'-dihydroxy-6,10',15'-trimethyl-6',12',14'-trioxaspiro[oxane-2,5'-tetracyclo[11.3.1.0²,¹¹.0³,⁸]heptadecane]-2',8',10'-trien-13'-ylmethyl}-2,4-dihydroxy-3-methylbenzaldehyde

C30H36O9 (540.2359)

(13r,15r)-15-[(1z)-2-(7-hydroxy-2-oxochromen-6-yl)ethenyl]-11,11,15-trimethyl-8-(2-methylbut-3-en-2-yl)-6,10,16-trioxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1,3,7,9(17)-tetraen-5-one

C33H32O7 (540.2148)

(1r,2s,3s,4as,6r,8r,8ar)-2,6-bis(acetyloxy)-8-[(1e)-2-ethenyl-3-oxobut-1-en-1-yl]-3-hydroxy-4,4,8a-trimethyl-7-oxo-hexahydro-1h-naphthalen-1-yl benzoate

C30H36O9 (540.2359)

2-(1-{5-[1-(2-hydroxyphenyl)prop-2-en-1-yl]-2,4-dimethoxyphenoxy}-1-phenylpropan-2-yl)-5-methoxycyclohexa-2,5-diene-1,4-dione

C33H32O7 (540.2148)

(1s,2r,4s,7s,8s,10r,11r,12s,17r,19r)-19-(acetyloxy)-7-(furan-3-yl)-1,8,12,16,16-pentamethyl-5,15-dioxo-3,6-dioxapentacyclo[9.8.0.0²,⁴.0²,⁸.0¹²,¹⁷]nonadec-13-en-10-yl acetate

C30H36O9 (540.2359)

(1r,2r,8r,11r,12r,14r,16s,17r,18r,19r)-19-(acetyloxy)-16-(furan-3-yl)-2,7,7,11,17-pentamethyl-5,10-dioxo-6,13-dioxapentacyclo[9.8.0.0²,⁸.0¹²,¹⁴.0¹²,¹⁷]nonadec-3-en-18-yl acetate

C30H36O9 (540.2359)

nimbin (chemical)

C30H36O9 (540.2359)

(3r,3ar,6s,6as,9as,9br)-3-{2-[(6s,6as,9as,9br)-6a-hydroxy-6,9a-dimethyl-2,9-dioxo-4h,5h,6h,9bh-azuleno[4,5-b]furan-3-yl]ethyl}-3,6a-dihydroxy-6,9a-dimethyl-3ah,4h,5h,6h,9bh-azuleno[4,5-b]furan-2,9-dione

C30H36O9 (540.2359)

methyl 2-[(1r)-2-[(1as,3s,3ar,4r,5s,6r,7as)-4,5-bis(acetyloxy)-3-(furan-3-yl)-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxiren-6-yl]-6,6-dimethyl-5-oxocyclohex-3-en-1-yl]acetate

C30H36O9 (540.2359)

2,6-bis(acetyloxy)-8-(2-ethenyl-3-oxobut-1-en-1-yl)-3-hydroxy-4,4,8a-trimethyl-7-oxo-hexahydro-1h-naphthalen-1-yl benzoate

C30H36O9 (540.2359)

(1r,2r,3r,4r,5r,7r,8r,9r,11s,12z,14r,17s)-7,9-bis(acetyloxy)-4,5,11-trihydroxy-4,8,12,17-tetramethyl-16-oxo-15,18-dioxatetracyclo[12.4.0.0¹,¹⁷.0³,⁸]octadec-12-en-2-yl acetate

C26H36O12 (540.2207)

(2s,4s,6s,9r,12r,16s,17s,18r,19r)-19-(acetyloxy)-16-(furan-3-yl)-4-hydroxy-8,8,12,17-tetramethyl-3,11-dioxo-7-oxapentacyclo[10.7.0.0²,⁶.0²,⁹.0¹³,¹⁷]nonadec-13-en-18-yl acetate

C30H36O9 (540.2359)

13-{15,16-dimethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,13,15-heptaen-8-yl}-3,5-dioxa-11-azapentacyclo[10.7.1.0²,⁶.0⁸,²⁰.0¹⁴,¹⁹]icosa-1(20),2(6),7,12,14(19),15,17-heptaene

C35H28N2O4 (540.2049)

(2r,3r,4s,5s,6r)-2-[3-(4-{[(1r,2r)-1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy}-3-methoxyphenyl)propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

(1r,2s,3s,4s,5s,7s,8r,9s,11r,12z,14s,17r)-7,9-bis(acetyloxy)-2,4,5-trihydroxy-4,8,12,17-tetramethyl-16-oxo-15,18-dioxatetracyclo[12.4.0.0¹,¹⁷.0³,⁸]octadec-12-en-11-yl acetate

C26H36O12 (540.2207)

1-{[(1r,4z,8e,10z,12s,15r,17s)-17-[(4r)-2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl]-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl]oxy}-n-phenylmethanimidic acid

C29H36N2O6S (540.2294)

(2r,3r,4s,5s,6r)-2-[3-(4-{[(1s,2s)-1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy}-3-methoxyphenyl)propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

15-[2-(7-hydroxy-2-oxochromen-6-yl)ethenyl]-11,11,15-trimethyl-8-(2-methylbut-3-en-2-yl)-6,10,16-trioxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1,3,7,9(17)-tetraen-5-one

C33H32O7 (540.2148)

(1s,4s,7z,10s,16e,21r)-7-ethylidene-6,9,19,22-tetrahydroxy-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricosa-5,8,16,19,22-pentaen-3-one

C24H36N4O6S2 (540.2076)

15-[(1e)-2-(7-hydroxy-2-oxochromen-6-yl)ethenyl]-11,11,15-trimethyl-8-(2-methylbut-3-en-2-yl)-6,10,16-trioxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1,3,7,9(17)-tetraen-5-one

C33H32O7 (540.2148)

(2r,3r,4s,5s,6r)-2-[(1s,2r)-3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2-methoxyphenoxy]propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

n-(3-chloropropyl)-1-{[(1r,4z,8e,10z,12s,15r,17s)-17-[(4r)-2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl]-5,12-dimethyl-3-oxo-2,16-dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl]oxy}methanimidic acid

C26H37ClN2O6S (540.2061)

(2r,3r,4s,5s,6r)-2-[(2s,3r)-3-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2-methoxyphenoxy]propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

5-ethenyl-1-oxo-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3h,4h,4ah,5h,6h-pyrano[3,4-c]pyran-3-yl (2e,6z)-8-hydroxy-2,6-dimethylocta-2,6-dienoate

C26H36O12 (540.2207)

(2s,3r,4s,5s,6r)-2-{4-[(1s,2r)-1,3-dihydroxy-2-[4-(3-hydroxypropyl)-2-methoxyphenoxy]propyl]-2-methoxyphenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C26H36O12 (540.2207)

[(2r,3s,4s,5r,6r)-6-{[(2r)-4-[(1s,5r,8r)-1,5-dimethyl-3-oxo-6-oxabicyclo[3.2.1]octan-8-yl]butan-2-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl 3,4,5-trihydroxybenzoate

C26H36O12 (540.2207)

(1s,2r,4s,7s,8s,11r,12r,18r,19s)-19-(acetyloxy)-7-(furan-3-yl)-1,8,12,16,16-pentamethyl-5,15-dioxo-3,6-dioxapentacyclo[9.8.0.0²,⁴.0²,⁸.0¹²,¹⁷]nonadec-13-en-18-yl acetate

C30H36O9 (540.2359)

7,11-bis(acetyloxy)-2,4,5-trihydroxy-4,8,12,17-tetramethyl-16-oxo-15,18-dioxatetracyclo[12.4.0.0¹,¹⁷.0³,⁸]octadec-12-en-9-yl acetate

C26H36O12 (540.2207)

methyl (3s,4as,5r,6r,6as,7s,11as,11br)-6-(acetyloxy)-3-(benzoyloxy)-4a,5-dihydroxy-4,4,11b-trimethyl-1h,2h,3h,5h,6h,6ah,7h,11h,11ah-phenanthro[3,2-b]furan-7-carboxylate

C30H36O9 (540.2359)

n-[(2z)-2-(butan-2-ylidene)-7,10-dihydroxy-5,11-dimethyl-3,12-dioxo-9-(pyridin-3-ylmethyl)-1,4-dioxa-8-azacyclododec-7-en-6-yl]-3-hydroxypyridine-2-carboximidic acid

C27H32N4O8 (540.222)